Skip to main content
. 2020 Dec 18;10(12):e038867. doi: 10.1136/bmjopen-2020-038867

Figure 3.

Figure 3

Probabilistic sensitivity analyses for pembrolizumab versus standard-of-care (SOC) therapy. (A) Cost-effectiveness (CE) acceptability curve; and (B) cost-effectiveness plane. PEM, pembrolizumab; QALY, quality-adjusted life years; WTP, willingness to pay.